Executive Chairman and former President, Chief Executive Officer and Chief Scientific Officer · Sagimet Biosciences Inc. (SGMT)

George Kemble

A named executive officer of Sagimet Biosciences in every fiscal year CompBrief holds from FY2022 to FY2023. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2023

$930,223

Salary $458,630Stock awards $446,220

FY2022: $574,866

3rd of 4 named executive officers at Sagimet Biosciences by FY2023 total.

4 named officers on file for Sagimet Biosciences, FY2023

George Kemble’s pay file — $29

  • 2 fiscal years of pay, line by line
  • 1 equity grant, each cited to its filing

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Sagimet Biosciences’s whole pay program stands against its peers

  • Sagimet Biosciences’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on SGMT→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 18, 2024 (DEF 14A).

Free

Get George Kemble’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

George Kemble compensation by year

Sagimet Biosciences Summary Compensation Table · all 2 fiscal years held
In US dollars, as Sagimet Biosciences reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2022FY2023
Salary$404,856$458,630
Bonus$0$0
Stock awards$0$446,220
Option awards$129,713$0
Non-equity incentive$0—
Pension and deferred compensation$0$0
All other$40,297$25,373
Total$574,866$930,223

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Sagimet Biosciences Inc. DEF 14A filed April 18, 2024, accession 0001104659-24-048534, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Sagimet Biosciences Inc. filed document, accession 0001104659-24-048534. Every figure is read from that document and cited to the page and table it appears in. Filed April 18, 2024.

$575K
$930K
FY22
FY23
SalaryStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2023 year-end
TypeUnvested unitsValue at year-endExercise price
RSU150,750$817,065—
Option142,544—$6.36
Option14,996—$7.15

Per the Outstanding Equity Awards at Fiscal Year-End table in Sagimet Biosciences Inc.'s FY2023 proxy; value at the fiscal year-end close, as the company printed it.

Sagimet Biosciences’s named executive officers, FY2023

as the company reported each
Named executive officerRoleFY2023 total
David HappelPresident and Chief Executive Officer$2,685,917
Eduardo MartinsChief Medical Officer$1,509,081
George Kemble · this pageExecutive Chairman and former President, Chief Executive Officer and Chief Scientific Officer$930,223
Dennis HomFormer Chief Financial Officer$745,507

Board service

Sagimet Biosciences board · FY2024–FY2025
Director compensation in US dollars, as Sagimet Biosciences reports it. Most recent year first; a dash means the company reported no figure in that column.
Fiscal yearCash feesStock awardsOption awardsOtherTotal
FY2025$45,726$129,864—$0$175,590
FY2024—————

Each year as the company reported it in Sagimet Biosciences's director compensation table. Totals are the company's own disclosed totals.

How this board is paid

Company policy: Sagimet Biosciences pays directors a $40,000 cash retainer and $130,050 in Options. As stated in Sagimet Biosciences's FY2025 proxy.

The full Sagimet Biosciences compensation record

free company brief

This page is one person within Sagimet Biosciences's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Sagimet Biosciences's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

George Kemble's compensation dossier · One-time report. No refunds.